Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2009

View Archived Issues

Fewer flu-like symptoms seen with CR interferon alfa-2b vs. peginterferon alfa-2b

Piperacillin/tazobactam as prophylactic for febrile complications in prostate needle biopsy

Butylphthalide lessens stroke impact in clinical study

Vertex updates pipeline progress

Periocular delivery of EDL-155 depletes retinoblastoma tumor growth in rats

Endothelin receptor type A antagonist avosentan shows antiglaucoma activity in monkeys

Acucela presents novel isomerase inhibitors for the treatment of AMD

FDA awards fast track designation to Ark's Trinam

PharmaGap ships PhG-alpha-1 cancer drug to NCI for testing

BioCancell reports results from compassionate-use trial of BC-819 in TCC

Merck Serono launches powder formulation of Glucophage in France and U.K.

MorphoSys achieves milestone under HuCAL-derived antibody alliance with Novartis

Pacgen signs letter of intent to acquire Xphase

FDA grants marketing approval to Vanda's Fanapt for schizophrenia

ProStrakan files response to the FDA's action letter regarding the NDA for Fortigel

FDA grants accelerated approval of Avastin for glioblastoma

ChemoCentryx identifies C5aR antagonist CCX-168 as development candidate

Mycophenolate mofetil may be used in patients with chronic inflammatory demyelinating polyneuropathy

Novel antimigraine compounds claimed by Lilly

AstraZeneca describes novel protein kinase B inhibitors for cancer treatment

Novartis claims novel serine protease inhibitors for the treatment of hepatitis C virus

Novel PPAR agonists for the treatment of diabetes discovered by GlaxoSmithKline

FDA grants orphan drug designation to Hyperion's HPN-100 for urea cycle disorders

Genelux reports development of oncolytic virus with antitumor and tumor imaging potential

Monoclonal antibody MBL-HCV1 protects chimpanzees from HCV infection

Novartis receives European approval for Glivec for cancer recurrence following surgery for GIST

FDA approves VeroScience's Cycloset for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...